oncology– tag –
-
Biotech Investment
Biotech Investment News: Amgen’s Key Deals from 2015 to 2025
Strategic Review: From Biologics to Rare Diseases, Oncology, and RNA Innovation Over the past decade, Amgen has expanded beyond its legacy focus on bone and inflammatory diseases to invest heavily in oncology, RNA therapies, and rare dis... -
Biotech Investment
Biotech Investment News: Eli Lilly’s Key Deals from 2015 to 2025
Strategic Overview: Dominance in Diabetes and Obesity with Oncology Expansion Eli Lilly has strengthened its global leadership in diabetes and obesity while expanding into oncology, neuroscience, and gene therapy. With the blockbuster su... -
Biotech Investment
Biotech Investment News: GSK’s Major Deals from 2015 to 2025
Strategic Review: Focused Expansion in Vaccines and Specialty Medicines Over the past decade, GSK has shifted from large-scale M&A to focused investments and strategic partnerships, particularly in vaccines, oncology, respiratory, an... -
Biotech Investment
Biotech Investment News: AstraZeneca’s 10-Year Deal Overview & 2025 Update (2015–2025)
Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S... -
Biotech Investment
Biotech Investment News: Bristol Myers Squibb’s Major Deals (2015–2025)
Strategic Review: From Opdivo to Next-Gen Modalities BMS is known as a pioneer in immuno-oncology, with the development of Opdivo (nivolumab) and Yervoy (ipilimumab). Over the past decade, the company has expanded aggressively into new m... -
Biotech Investment
Biotech Investment News: Roche’s Major Deals Over the Past Decade (2015–2025)
Strategic Review: Expanding from Monoclonal Antibodies into Diagnostics, RNA, and Cell Therapy Roche has long been a global leader in monoclonal antibody-based cancer therapies. Roche has long been a global leader in monoclonal antibody-...